GLIOBLASTOMA

This trial is testing a personalized vaccine made from unique proteins (neoantigens) found in a person's tumor. The goal is to see if the vaccine is safe and can help slow or stop cancer growth in people with solid tumors, including pancreatic cancer. About 136 participants with …

This Phase 3 trial compares the drug niraparib to the standard chemo temozolomide in 450 adults with newly diagnosed, aggressive glioblastoma that has a specific genetic marker (MGMT unmethylated). Participants take the assigned drug daily during radiation, then continue until th…

This study tests a mix of immune-boosting drugs, natural killer cells, and a device that sends low-intensity electric fields to the brain for people with glioblastoma that has come back after initial treatment. The trial has two parts: first, everyone gets the drug combo; second,…

This trial tests whether a new type of MRI, called MR fingerprinting, can better show where a glioblastoma (an aggressive brain tumor) has spread compared to standard MRI. The goal is to help surgeons remove more of the tumor safely. The study involves adults with suspected gliob…

This early-phase trial tests a new drug called Peposertib, combined with radiation and chemotherapy, for people with a hard-to-treat type of brain cancer called glioblastoma. The study aims to find the best dose and check safety in 29 participants. If it works, the drug may help …

This study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether adding a second chemotherapy drug, lomustine, to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma live longer. The trial includes 265 adults with newly diagnosed tumors that have a methylated MGMT gene…

This phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…

This study tested a new drug called veliparib, given with radiation and chemotherapy, for children and young adults with a fast-growing brain tumor (high-grade glioma). The goal was to see if adding veliparib helps keep the cancer from coming back longer than standard treatment. …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests whether adding veliparib to the standard chemotherapy drug temozolomide helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The trial includes 447 patients whose tumors have a specific genetic change (MGMT promoter hypermethylation).…

This early-phase trial is testing the immunotherapy drug nivolumab in children and young adults whose high-grade glioma has come back or is getting worse. Participants receive the drug before and after surgery to remove as much of the tumor as possible. The main goals are to chec…

This study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if …

This early-stage study tests whether adding a drug called acetazolamide to standard chemotherapy (temozolomide) is safe for people with a newly diagnosed, aggressive brain cancer (glioblastoma). Ten adults will take both drugs daily for 21-day cycles. The main goal is to find any…

This early-stage trial tests a new surgical approach for recurrent glioblastoma, an aggressive brain cancer. After standard tumor removal, surgeons place a piece of abdominal tissue (omentum) into the brain cavity to bypass the blood-brain barrier. The study involves 10 adults an…

This phase 2 trial tests whether two targeted drugs, dabrafenib and trametinib, can improve outcomes for children and young adults with a specific type of high-grade glioma (BRAF V600-mutant) after they receive radiation therapy. The study enrolls 58 participants aged 25 or young…

This phase 2 trial tests whether adding a dendritic cell vaccine and an immune-boosting drug (varlilumab) to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. About 43 participants will receive the vaccine plus temozolomide, with some also getti…

This phase 1 trial tests a radioactive drug called Lutathera in people with glioblastoma, an aggressive brain cancer. The study includes two groups: newly diagnosed patients receiving Lutathera with standard radiation and chemotherapy, and patients with recurrent glioblastoma rec…

This study planned to test a two-part experimental treatment for newly diagnosed glioblastoma, a fast-growing brain cancer. The treatment combined a modified virus (Toca 511) designed to enter tumor cells and an extended-release antifungal drug (Toca FC) that the virus helps turn…

This early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …

This early-stage trial tested a personalized DNA vaccine designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. Nine patients with a specific type of glioblastoma (unmethylated MGMT) received the vaccine along with an immune booster. The main goa…

This early-phase trial tests whether adding two experimental DNA vaccines (INO-5401 and INO-9012) and an immunotherapy drug (cemiplimab) to standard radiation and chemotherapy is safe and helps people with newly-diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults…

This early-stage trial tests a therapy made from a patient's own immune cells, engineered to target a protein called B7-H3 found on glioblastoma cells. The cells are delivered directly into the brain via a small device. The study aims to find a safe dose and check for any signs t…

This study tests whether adding weekly MRI scans during radiation treatment can help doctors better target high-grade gliomas, a type of aggressive brain tumor. About 20 adults with newly diagnosed tumors will receive standard radiation plus extra imaging to see if it improves tr…

This study tests whether adding the drug daratumumab to standard chemotherapy and radiation can help people with a newly diagnosed aggressive brain cancer called glioblastoma. About 16 participants will receive the combination treatment. The goal is to see if the new approach imp…

This study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in ad…

This early-phase trial tests a combination of two drugs (domvanalimab and zimberelimab) that aim to help the immune system fight glioblastoma, an aggressive brain cancer that has returned after initial treatment. About 46 participants will receive the drugs to check safety and se…

This early-phase trial tests a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with radiation and the immunotherapy drug pembrolizumab (Keytruda), in people with newly diagnosed glioblastoma. The main goals are to see if the vaccine can be …

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This phase II trial tests the drug trametinib in people whose advanced cancers have specific genetic changes called GNAQ or GNA11 mutations. The drug works by blocking certain proteins that help cancer cells grow. Researchers want to see if trametinib can shrink these tumors or s…

This early-stage trial tests whether specially engineered immune cells are safe and feasible for people with a recurring type of brain cancer called glioblastoma. The cells are designed to recognize and attack two specific proteins found on the cancer cells. The study involves 67…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This phase 2 trial tests the drug azeliragon, taken as a capsule, together with radiation therapy for people with a specific type of glioblastoma (a fast-growing brain cancer). The study includes 30 participants whose tumors lack a certain DNA marker (MGMT unmethylated). The goal…

This phase 3 trial tests whether giving the chemotherapy drug temozolomide earlier and for a longer time can help adults with glioblastoma live longer. About 486 participants will receive either the standard treatment or an intensified version that starts chemo within two weeks o…

This phase II study tests a vaccine called SurVaxM, designed to train the immune system to attack glioblastoma cells, when given alongside standard chemotherapy (temozolomide). The trial includes 66 patients with newly diagnosed, survivin-positive glioblastoma or gliosarcoma. The…

This phase 2 trial tests whether giving a higher, more targeted dose of radiation—guided by advanced MRI scans—along with standard chemotherapy (temozolomide) can improve survival in 30 people with newly diagnosed glioblastoma, an aggressive brain cancer. The radiation is adapted…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults with this diagnosis will receive the combination therapy. The main goals are…

This early-stage trial tests the immunotherapy drug pembrolizumab in 60 adults with recurrent glioblastoma, an aggressive brain cancer. The study aims to see how the drug affects immune cells in the tumor and whether it is safe. Participants receive pembrolizumab before and after…

This early-phase study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in teens and young adults with a type of brain tumor called glioma that has an IDH mutation. The goal is to find the safest dose and see how well the combination works for both newly diagn…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain tumor called glioblastoma (grade 4 glioma). The study includes both newly diagnosed and recurrent patients. First, researchers measure how much dru…

This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives…

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This early-phase trial tests a new treatment for adults with aggressive brain cancers (glioblastoma, ependymoma, or medulloblastoma) that have spread to the lining of the brain and spinal cord. The treatment uses the patient's own immune cells, modified in a lab to recognize and …

This trial tests whether removing a wider margin of brain tissue around a glioblastoma tumor (supramarginal resection) improves survival compared to standard surgery. It involves 90 patients with suspected glioblastoma who are considered good candidates for the more extensive sur…

This early-phase trial is testing whether giving two immune-boosting drugs (nivolumab and ipilimumab) before surgery can help fight recurrent glioblastoma, a fast-growing brain cancer. About 63 adults whose tumor has returned after standard treatment will receive the drugs or a p…

This phase 2b trial tests IGV-001, a personalized immunotherapy made from each patient's own tumor cells, for newly diagnosed glioblastoma. About 93 participants receive either IGV-001 or a placebo, along with standard radiation and chemotherapy. The goal is to see if the treatme…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This pilot study tests whether an energy-restricted ketogenic diet (ERKD) can help control glioblastoma, an aggressive brain cancer. Sixteen adults with newly diagnosed glioblastoma will follow the diet while receiving standard radiation and chemotherapy. The goal is to see if th…

This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (temozolomide chemotherapy and Tumor Treating Fields) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 40 adults with this aggressive brain …

This phase II trial compares a short course of high-dose radiation (over fewer days) to the standard longer course for people with glioblastoma, an aggressive brain cancer. The goal is to see if the shorter treatment is just as good at keeping patients alive while possibly causin…

This early-phase trial tests a new immune cell therapy for people with recurrent or treatment-resistant malignant glioma, a type of brain cancer. The treatment uses the patient's own T cells, modified in the lab to recognize and attack cancer cells. The main goal is to find the s…

This study tests a precise type of radiation therapy (IM-SRT) for people with newly diagnosed grade II to IV gliomas. The goal is to deliver a high dose of radiation directly to the tumor while minimizing damage to the scalp, which may reduce wound infections and the need for met…

This study tests whether adding the experimental drug BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 50 adults with this aggressive brain tumor will receive the co…

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. A…

This clinical trial tests a new drug called vebreltinib (PLB1001) in people with a recurrent form of glioblastoma that has a specific genetic change (ZM fusion gene). The study compares vebreltinib to standard chemotherapy to see if it helps people live longer. About 84 participa…

This early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 6…

This phase 2 trial compares two types of higher-dose radiation (IMRT or proton beam) plus the chemotherapy drug temozolomide against standard radiation plus temozolomide in 606 people with newly diagnosed glioblastoma. The goal is to see if the higher-dose approaches improve over…

This study tests whether adding an experimental drug called indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children wi…

This phase 2 trial tests a combination of the drug niraparib and a device that delivers electric fields (Tumor-Treating Fields) in 30 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the combo can control the tumor, shrink it, or keep it stabl…

This phase II trial tests whether adding the immunotherapy drug nivolumab to re-irradiation and bevacizumab can help people with recurrent glioblastoma live longer. The study includes 39 participants whose tumors have a specific genetic marker (MGMT methylated). The goal is to se…

This study tests whether adding the drug anlotinib hydrochloride to the standard Stupp regimen (chemoradiation) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with this aggressive brain tumor are participati…

This study tests a combination of an experimental drug (paxalisib), a diabetes drug (metformin), and a high-fat, low-carbohydrate ketogenic diet in people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach is safe and can slow tumor growth. The tri…

This study tests whether a ketogenic diet (high fat, low carb) combined with the diabetes drug metformin is safe and tolerable for people with glioblastoma, an aggressive brain cancer. The idea is to lower blood sugar, which tumors use to grow. The 18 participants prepare their o…

This early trial tests two oral drugs, defactinib and VS-6766, in 14 people with glioblastoma. The goal is to see how much drug reaches the brain tumor and check for side effects. Both drugs block different growth pathways that help glioblastoma cells grow. This study only looks …

This early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…

This study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…

This early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a sa…

This study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olapari…

This study tests if the immunotherapy drug nivolumab can stop or slow the growth of certain brain tumors (gliomas) that have IDH mutations. Researchers are especially interested in tumors with many genetic changes (hypermutator phenotype). The trial involves 62 adults who receive…

This phase I/II trial tests a combination of immune cells (dendritic cells) and two immunotherapy drugs (ipilimumab and nivolumab) for people with recurrent glioblastoma, an aggressive brain cancer. The treatment is given directly into the tumor during surgery, followed by more d…

This early-stage study tests an oral drug called gallium maltolate in 26 people whose glioblastoma (a severe brain cancer) has returned after prior treatment. The main goal is to find a safe dose and see if it can slow tumor growth. Participants take the drug by mouth and are mon…

This phase 3 trial tests whether giving a dose of radiation directly to the tumor site during surgery (intraoperative radiotherapy) can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without their cancer growing. The study involves 314 …

This early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…

This program gives certain glioblastoma patients access to SurVaxM, a drug that helps the immune system fight brain cancer. It is for patients who cannot join other trials or who have already benefited from SurVaxM in a previous study. The treatment involves four doses given two …

This early-phase trial tests whether a personalized vaccine made from each patient's tumor mutations, combined with Tumor Treating Fields (a device that sends electric fields to the brain), is safe and feasible for people with newly diagnosed glioblastoma. The 13 participants rec…

This study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor …

This study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial …

This early study tests a new imaging technique called qOBM that may help brain surgeons see tumor edges more clearly during surgery. About 24 adults with certain brain tumors (glioblastoma, astrocytoma, or oligodendroglioma) will have the device used during their planned tumor re…

This study is testing a new type of MRI scan that looks at sodium and other chemicals in the brain to get a clearer picture of brain tumors (gliomas). The goal is to improve how doctors detect, diagnose, and track these tumors. The study includes healthy volunteers and people wit…

This study tests an online mind-body program designed for people with brain tumors (glioma) and their partners. The program aims to improve spiritual well-being, sleep, mood, and overall quality of life for both. Researchers are enrolling 74 couples to see if the program is pract…

This study looks at whether a large database of patient health records (Truveta) can be used as a control group for a glioblastoma drug called BPM31510. Glioblastoma is a fast-growing brain tumor, and it is hard to run traditional placebo-controlled trials because the disease is …

This study tests whether using an app for patients to report symptoms can guide when to do MRI scans, instead of following a fixed schedule. It involves 20 adults with newly diagnosed glioblastoma. The goal is to see if this approach is feasible and acceptable, not yet to prove i…

This study collects multiple samples from different parts of a glioblastoma tumor during surgery. Researchers will analyze the samples to learn how genetic changes vary within a single tumor. The goal is to improve future diagnosis and treatment of brain tumors. The study involve…

This study looks at whether simple blood tests can help doctors understand how glioblastoma, a serious brain cancer, changes over time. About 100 newly diagnosed patients will give blood samples before and after standard radiation and chemotherapy. The goal is to see if DNA from …

This study tests a new ultrasound system (SonoClear®) that uses a special gel to mimic brain tissue, aiming to give surgeons clearer images during brain tumor removal. Fifteen adults with glioma (a type of brain tumor) are participating. The main goal is to see if the new system …

This study explores whether an Apple Watch can track walking, heart rate, breathing, and sleep in people with glioblastoma, a serious brain cancer. The goal is to see if the watch can detect symptom changes before they become serious, like seizures or blood clots. Twenty-five pat…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at how doctors, patients with glioblastoma (a serious brain cancer), and their caregivers talk about the disease, scan results, and treatment choices. Researchers will use surveys and tests to understand these conversations. The goal is to find ways to improve co…

This study is not testing a new treatment. Instead, researchers are reviewing medical records from 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how well past chemotherapy and targeted therapies worked. The goal is to learn which treatments are lin…

This study collects blood and bone marrow samples from 40 adults with newly diagnosed glioblastoma to track changes in immune cells over time. Researchers aim to understand how the immune system responds to the tumor and standard treatments. The goal is to gather foundational dat…

This study looks at whether advanced MRI scans can predict how well Optune therapy works in people with newly diagnosed glioblastoma, a type of brain cancer. Researchers will compare standard and advanced MRI in 60 participants to see which better forecasts survival at six months…